Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Target Price at $156.50

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have received a consensus recommendation of “Moderate Buy” from the fifteen analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and thirteen have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $156.50.

A number of brokerages recently issued reports on ABVX. Leerink Partners raised their price target on Abivax from $140.00 to $148.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 30th. Guggenheim reiterated a “buy” rating on shares of Abivax in a research note on Tuesday, June 30th. Piper Sandler lifted their target price on Abivax from $165.00 to $175.00 and gave the stock an “overweight” rating in a research report on Thursday, July 9th. Wolfe Research set a $136.00 target price on shares of Abivax in a research note on Wednesday, June 3rd. Finally, Truist Financial upped their price target on shares of Abivax from $135.00 to $155.00 and gave the stock a “buy” rating in a report on Thursday, July 2nd.

Abivax Price Performance

Shares of NASDAQ:ABVX opened at $111.08 on Thursday. The firm has a market capitalization of $9.69 billion, a PE ratio of -21.32 and a beta of 0.96. The business has a 50 day simple moving average of $125.32 and a two-hundred day simple moving average of $118.78. Abivax has a 1 year low of $69.81 and a 1 year high of $148.83.

Institutional Investors Weigh In On Abivax

Large investors have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its stake in Abivax by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock worth $41,000 after acquiring an additional 1,990 shares in the last quarter. Cubist Systematic Strategies LLC boosted its holdings in shares of Abivax by 34.3% in the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock valued at $63,000 after purchasing an additional 2,595 shares during the period. Millennium Management LLC boosted its holdings in shares of Abivax by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after purchasing an additional 56,235 shares during the period. Woodline Partners LP grew its stake in Abivax by 319.5% in the first quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after purchasing an additional 153,788 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Abivax in the second quarter worth approximately $139,000. 47.91% of the stock is owned by hedge funds and other institutional investors.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.